In an age where lifestyle diseases are on the rise and people are increasingly searching for natural and sustainable ways to heal, Dr. Venkataramana Hegde stands out as a guiding force in the field of Naturopathy and Ayurveda. A renowned physician, respected medical writer, and passionate health educator, Dr. Hegde has dedicated his life to bringing the wisdom of Naturopathy and Ayurveda into everyday living.

Based in Sirsi, Uttara Kannada, Dr. Hegde is the Chief Medical Officer of Veda Wellness Center at Nisargamane, Ganesh Nagar. For over two decades, he has been helping people overcome chronic and difficult-to-treat illnesses through a holistic approach that combines Ayurveda, diet therapy, and Naturopathy.

National Recognition at the World Ayurveda Conference

Dr. Hegde’s contributions recently received international recognition when he was felicitated at the World Ayurveda Conference, held at the Palace Grounds, Bengaluru. The prestigious honour was presented by Dr. Giridhar Kaje and Dr. Mallepuram Venkatesh, in the presence of eminent medical professionals including Dr. C. N. Manjunath, Dr. G. Senthival, Dr. B. T. Rudresh, Dorje Rothen Nesher, and Dr. Manjula S. The award stands as a testament to his lifelong commitment to healing and public health education.

A Trusted Voice in Health Communication

Beyond clinical practice, Dr. Hegde has played a pivotal role in health communication. He has become a familiar and trusted name among Kannada readers and viewers through his long-running columns and television programs. His popular contributions include the “Dhanvantari” column in Vijayavani, the television program “Nativaidya” on Udaya TV, “Āhāradalli ārōgya” on Praja TV, the unique health-meets-humor show “Nagomaddu” on Udaya Comedy, and health programs on Digvijaya Channel.

In the digital space, his YouTube channels “Ayurveda Tips in Kannada” and “Nisargamane Sirsi” continue to educate thousands, making Ayurvedic knowledge accessible and practical for modern households.

Author, Educator, and Health Reformer

Dr. Hegde is also a prolific writer, having authored nine widely read health books and penned over 6,000 articles published in leading Kannada newspapers. His bestselling books such as “Power Diet – rōga nivāraṇeya naisargika upāyagaḷu”, “Āhāra ārōgya”, “Aḍugemaneyē āspatre – āhāravē auṣadha” and “Manemaddu” have reached record sales and are considered must-have guides for families seeking natural well-being.  His writings focus on a simple yet powerful message: food is medicine, and everyday lifestyle choices hold the key to long-term health.

Touching Lives Through Service

Through Veda Wellness Center, Dr. Hegde has provided natural treatment to more than two lakh patients, many of whom had lost hope after other treatments failed. He regularly organizes health camps across Karnataka, extending his service to rural and underserved communities.

In addition, Dr. Hegde serves as a member of the advisory board for Vydyaloka and HealthVision monthly magazines, actively supporting the growth of health journalism and awareness.

A Life Dedicated to Healing

Having received several accolades over the years, the recognition at the World Ayurveda Conference marks yet another milestone in Dr. Venkataramana Hegde’s inspiring journey. More than an award, it symbolizes the trust, respect, and gratitude of countless lives he has touched.

With his unwavering belief in nature’s healing power and his tireless efforts to educate society, Dr. Venkataramana Hegde continues to be a beacon of Naturopathy, holistic health and Ayurvedic wisdom in Karnataka and beyond.

Also Read :  Dr Venkatramana Hegde articles 

The post Dr Venkataramana Hegde – Felicitated at World Ayurveda Conference appeared first on Health Vision.

Ahmedabad: Cadila Pharmaceuticals, one of India’s most trusted healthcare companies, has launched Folistrong Hair Oil, a natural and science-backed formulation developed to nourish the scalp, strengthen hair from the roots, and promote overall hair health. The new product marks a major addition to the company’s growing wellness portfolio.

Folistrong Hair Oil is enriched with a unique blend of restorative natural ingredients, including Amla, Kalatil, Bhangraj, Haridra, Anaar, Sesame, Indigo, Arjun, Ashwagandha, Jasmine and Guduchi. Together, these ingredients work in synergy to rejuvenate the scalp and stimulate healthy hair growth.

The formulation accelerates hair growth and supports stronger roots, reduces hair fall, helps prevent breakage, and assists in controlling dandruff and flakiness, thereby promoting healthier scalp. It also helps protect natural hair colour, delays greying, and provides gentle conditioning to reduce split ends. Free from SLES, parabens, and mineral oil, Folistrong Hair Oil is suitable for all hair types and offers a clean, dependable option for everyday hair care.

Folistrong Hair Oil combines traditional botanical wisdom with Cadila’s extensive research expertise to present a holistic solution for those experiencing hair fall, dullness, or scalp-related concerns. Beyond strengthening hair, it enhances shine and smoothness.

Speaking at the occasion, Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals Limited, said, “With Folistrong, we aim to offer consumers a natural and trustworthy solution for their daily hair care needs. The product reflects our commitment to bringing safe, effective, and holistic wellness offerings to the market.”

Cadila Pharmaceuticals Ltd. is one of India’s leading integrated privately held pharmaceutical firms, located in Ahmedabad, Gujarat.
The firm develops and produces pharmaceutical products in India and sells and distributes them in over 100 countries. The organization places a high emphasis and priority on research, whether it is in biotechnology, APIs, formulations, plant tissue culture, or phytochemistry to innovate in various therapeutic areas including gastrointestinal, cardiology, pulmonary, oncology, gynaecology, cardiovascular, diabetology, and osteology.
Its undaunted commitment to create affordable miracles in therapeutic areas with significant unmet medical needs to serve society and the community at large has led to several world-first breakthroughs.

Also read more news of Cadila Pharmaceuticals

The post Folistrong Hair Oil – Cadila’s Natural Hair Care Solution appeared first on Health Vision.

Legacy of Two decades…Presenting you Cadila Herbals

Ahmedabad: Cadila Pharmaceuticals, one of India’s leading research-driven healthcare companies, has announced the launch of Cahaya Turmeric Cream, a new addition to its growing portfolio of nature-inspired wellness solutions. The cream has been thoughtfully developed to meet the rising demand for safe, natural, and effective skincare, addressing common concerns such as dullness, pigmentation, scars, fine lines, and uneven complexion.

At the core of the formulation is Curcuma longa (standardised turmeric extract)—a powerful natural ingredient revered for centuries for its therapeutic benefits. Known for its anti-inflammatory, antioxidant, and skin-brightening properties, turmeric plays a central role in restoring skin radiance and supporting healthy repair. Its active compounds absorb easily into the skin, promoting nutrition, soothing damaged areas, and enhancing overall texture and tone.

Created for dehydrated, dry, scaly, and environmentally stressed skin, Cahaya Turmeric Cream offers visible improvement in skin appearance through consistent use. The formulation is gentle, non-irritating, and enriched with natural ingredients that do not damage the skin, making it suitable for everyday skincare routines.

“Cahaya Turmeric Cream is more than just a skincare product—it is a thoughtful blend of time-honoured natural wisdom and modern research,” said Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals Pvt. Ltd. “Consumers today are increasingly mindful of what they apply on their skin. With Cahaya, we aim to offer a solution that is rooted in purity, backed by science, and designed to deliver meaningful results.”

Key Benefits of Cahaya Turmeric Cream

Brightens the skin, making it appear fresh, radiant, and rejuvenated
Lightens scars and reduces pigmentation, helping achieve visibly clearer skin
Improves complexion and supports an even, balanced skin tone
Aids in reducing fine lines and wrinkles, enhancing youthful appearance
Infused with natural, skin-friendly ingredients, ensuring safe and gentle care

Advancing Cadila’s Commitment to Holistic Wellness

The launch of Cahaya Turmeric Cream reinforces Cadila Pharmaceuticals’ continued focus on bringing innovations that combine natural ingredients with scientific formulation expertise. As consumer preferences shift towards clean, conscious, and ingredient-led skincare, Cahaya represents Cadila’s dedication to meeting evolving expectations with trusted, high-quality products.

Also read news of Cadila Pharmaceuticals

The post Cadila Launches Cahaya Turmeric Cream for Radiant Skin appeared first on Health Vision.

Ahmedabad: More than 20%, or one in five Indian women, suffer from bone and joint pain of rheumatic nature, according to World Health Organization’s (WHO) Community Oriented Programme for Control of Rheumatic Diseases (COPCORD) and leading rheumatology experts.

The survey of prevalence and risk factors of arthritis was led by Dr. Arvind Chopra, Director and Chief Rheumatologist, Center for Rheumatic Diseases, Pune, and Ayush Distinguished Scientist Chair for Public Health and Epidemiology, Government of India. The findings, based on a pooled analysis of data from a survey of more than 56,500 people in 21 urban and rural sites, were published in the International Journal of Rheumatic Diseases recently.

The findings based on simple extrapolation of study outcome data to the Indian population showed that 12.71 crore, or 65% of the 19.52 crore Indians suffering from arthritis pains, are women. The survey found that around 20-22% of women in India suffer from some kind of bone and joint pain of rheumatic nature.

More than 42.2 lakh Indias, of whom 35.1 lakh are women, suffered from rheumatoid arthritis, a potentially serious, crippling and extremely painful complex arthritis requiring special treatment. Rheumatoid arthritis is also a known cause of premature heart attacks and death. Around 11.7 lakh women suffering from rheumatoid arthritis were estimated to be young and in their reproductive age group, a number very high compared to other countries.

The survey findings were also presented and discussed during the two-day academic conclave organised in Ahmedabad by the Rheumatology Association Gujarat (RAG) and IIPH & Center for Rheumatic Diseases, Pune, on November 15 and 16. The conclave brought together leading experts, clinicians, researchers, and postgraduate students for learning, collaboration, and scientific exchange.

The two-day conclave has also announced the beginning of a new COPCORD survey, which will screen around 7,000 people in rural parts of Gujarat. The survey will focus on the incidence and prevalence of all kinds of rheumatic disease, not just arthritis. The data collection and publication will take around 6-8 months.

Sharing her insights, Dr. Reena Sharma, President of Rheumatology Association Gujarat, said, “Rheumatic and musculoskeletal disorders are among the most prevalent and burdensome conditions in India, but are neglected and under-reported. With crores of people in India, most of them women, living with arthritis-related pain, there is an urgent need for greater awareness, better integration between modern and traditional systems, and stronger clinical collaboration.”

According to the findings, 5.4 crore Indians live with osteoarthritis, commonly affecting the knees and spine. Osteoarthritis and lower back pain are the most common causes of disability. More than 1.72 crore people experience diffuse or localised musculoskeletal pain due to causes ranging from occupational strain, mental stress, age, poor lifestyle, and personal habits, including misuse of mobile phones. Manual labour, obesity, tobacco consumption, and low socio-economic status are among the other key risk factors. Moreover, arthritis pain was the number one self-reported illness amongst all recorded illnesses such as diabetes, hypertension, and stomach ailments.

Dr. Arvind Chopra, who has been conducting COPCORD surveys since 1996 and is the Chief Coordinator of India in global COPCORD studies, said, “Arthritic ailments are on the rise in India due to a variety of factors. It is not limited to urban areas but is also becoming a huge problem in rural areas. This conclave is an important step forward in understanding the burden and societal impact of arthritis in India, and in developing effective strategies for prevention and control of arthritis and related disorders by bringing together diverse disciplines.”

The conclave highlighted scientific sessions addressing critical frontline challenges such as Epidemiology and management of chikungunya fever and post-chikungunya arthritis, Common clinical dilemmas in patients with pre-existing autoimmune rheumatic disease, Burden of arthritis, Ayurvedic perspective on arthritis, and others.

Another highlight of the conference was the Scientific Writing Workshop, offering young clinicians and researchers’ practical insights into medical publishing.

The faculty and PG students from Medicine and Rheumatology, Community Medicine and Kayachikitsa (Ayurveda) from several medical institutions and colleges participated in the meeting.

Similar integrative meetings were organised in New Delhi, Pune, Gorakhpur, and Varanasi during August and October 2025 to discuss arthritis and increase awareness and knowledge in the community and medical faculty.

The post Rheumatic Ailment Hit Indian Women Hard – COPCORD Survey appeared first on Health Vision.

Ahmedabad: Cadila Pharmaceuticals, one of India’s most trusted and research-driven pharmaceutical companies, has launched Rosmi F, a fixed-dose combination of Rosuvastatin and Fenofibrate. This innovative therapy has been introduced to address the unmet clinical need in patients suffering from mixed dyslipidemia, a condition marked by elevated low-density lipoprotein (LDL) cholesterol and triglyceride levels that significantly increase cardiovascular risk.

In view of the rising incidence of lifestyle-related disorders such as diabetes, obesity, and cardiovascular diseases, Rosmi F provides a comprehensive lipid management solution that targets multiple lipid parameters simultaneously.

Rosmi F brings together two powerful lipid-lowering agents with complementary mechanisms. Rosuvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis, while Fenofibrate activates PPAR-α receptors to lower triglycerides and increase HDL-C.

Speaking on the launch, Dr. Rajiv I. Modi, Chairman & Managing Director of Cadila Pharmaceuticals Limited, said, “The introduction of Rosmi F is an important milestone in our efforts to address the growing burden of cardiometabolic disorders in India. Mixed dyslipidemia is a widespread yet often under-managed condition. Rosmi F offers clinicians an effective and scientifically validated tool to improve lipid control and reduce long-term cardiovascular risk. We look forward to its strong adoption and its impact on improving patient outcomes across the country.”

The scientifically proven synergy between rosuvastatin and fenofibrate helps improve lipid profiles more effectively. Together, they provide an integrated, guideline-aligned therapy designed to address elevated LDL-C, high triglycerides, and low HDL-C, common in metabolic syndrome, diabetes, and mixed dyslipidemia.

Evidence from global studies highlights the effectiveness of this combination. A 16-week study demonstrated a 53% reduction in triglycerides with fenofibrate, outperforming niacin extended release and without compromising insulin sensitivity. A 52-week open-label study showed patients achieving both LDL-C and HDL-C targets increasing from 19% at baseline to 50% at week 52 with rosuvastatin and fenofibrate therapy. These results align with leading guidelines, reinforcing the tablet’s clinical relevance and suitability.

The launch of Rosmi F further strengthens Cadila Pharmaceuticals’ leadership in the cardiometabolic therapy segment and reflects its commitment to delivering safe, innovative, and patient-centred healthcare solutions.

Also read news of Cadila Pharmaceuticals

The post Cadila Introduces Rosmi F Tablet for Lipid Management appeared first on Health Vision.

Ahmedabad: The Rheumatology Association Gujarat (RAG) is hosting a two-day academic conclave on November 15 and 16, bringing together leading experts, clinicians, researchers, and postgraduate students for an intensive weekend of learning, collaboration, and scientific exchange.

The conclave will feature two of India’s most distinguished figures in rheumatology, Dr. Arvind Chopra, Ayush Distinguished Scientist Chair and Director, Centre for Rheumatic Diseases, Pune, and Dr. Durga Prasanna Misra, Editor-in-Chief of Indian Journal of Rheumatology and Professor, Department of Clinical Immunology & Rheumatology, SGPGI, Lucknow.

Sharing details about the event, Dr. Reena Sharma, President of the Rheumatology Association Gujarat, said, “Rheumatic and musculoskeletal disorders are among the most prevalent and burdensome conditions in India, but are neglected and under-reported. With over 19.5 crore Indians living with arthritis-related pain, there is an urgent need for greater awareness, better integration between modern and traditional systems, and stronger clinical collaboration. This meeting aims to address exactly that by uniting diverse disciplines on a common platform to advance understanding and improve patient outcomes.”

According to recent data published by Dr. Chopra and colleagues under the WHO’s Community Oriented Programme for Control of Rheumatic Diseases (COPCORD), nearly 65% of arthritis sufferers in India are women, and one in five women in the country experiences bone and joint pain of a rheumatic nature. The team has completed 21 surveys covering more than 55,000 people, including 60% in rural areas.

The prevalence of rheumatoid arthritis (RA) is estimated at 0.5 to 0.8%. An earlier survey found 42 lakh cases of RA, including 35.1 lakh women and 11.7 lakh in young, reproductive-age women, reflects the immense social and economic impact of these disorders.

Additionally, 5.4 crore Indians live with osteoarthritis, commonly affecting the knees and spine. Osteoarthritis and lower back pain are the most common causes of disability. More than 1.72 crore people experience diffuse or localised musculoskeletal pain linked to occupational strain, stress, or poor lifestyle habits.

“Women are more prone to rheumatic diseases, while obesity, age, manual labour, tobacco consumption, and low socio-economic status are the other key risk factors,” said *Dr. Chopra, who has been conducting COPCORD surveys since 1996 and is the Chief Coordinator of India in global COPCORD studies.

Against this backdrop, the two-day conference will explore epidemiology, clinical management, public health perspectives, and integrative approaches to arthritis and autoimmune rheumatic diseases.

The conference will also mark the beginning of a new COPCORD survey, which will screen around 7,000 people in rural parts of Gujarat. The survey will focus on the incidence and prevalence of all kinds of rheumatic disease, not just arthritis. The data collection and publication will take around 6-8 months.

On the first day of the conference, scientific sessions will address critical frontline challenges such as “Epidemiology and Management of Chikungunya Fever and Post-Chikungunya Arthritis”, “Clues to Clinch the Diagnosis of Vasculitis in Medical OPDs”, and “Common Clinical Dilemmas in Patients with Pre-existing Autoimmune Rheumatic Disease”.

The following day will see sessions focusing on “Burden of Arthritis: A COPCORD Data Perspective” by Dr. Arvind Chopra, and “Arthritis: An Ayurvedic Perspective,” followed by interactive sessions on “Function and Quality of Life” and a hands-on workshop on Quality of Life (QOL) assessment.

Another highlight of the conference will be the Scientific Writing Workshop, offering young clinicians and researchers practical insights into medical publishing. The sessions include “Beyond the p-value: Weaving Statistics into a Compelling Narrative,” “Anatomy of a Manuscript: A Deep Dive into the IMRaD Framework,” and “Thinking Like a Reviewer: A Live Manuscript Autopsy”.

The event aims to promote multidisciplinary collaboration between rheumatology, internal medicine, public health, and Ayurvedic systems, a model of integrative learning that aligns with India’s growing emphasis on evidence-based holistic medicine.

Dr. Reena Sharma added, “Our goal is to create a platform that empowers clinicians and researchers to combine scientific precision with compassionate patient care. By linking modern rheumatology with Ayurveda and public health, we can move closer to developing effective strategies for prevention and control of arthritis and related disorders.”

Arthritis and Autoimmune disease meet – The two-day meeting promises to be an important step forward in understanding the burden, spectrum, and societal impact of arthritis in India, and in strengthening the bridge between science, service, and society.

The faculty and postgraduate students from Medicine and Rheumatology, Community Medicine and Kayachikitsa (Ayurveda) from several medical institutions and colleges are participating in the meeting. Dr. Sapan Pandya, Vice-President Indian Rheumatology Association and Senior Rheumatologist in Ahmedabad, Dr. Deepak Saxena, Director of IIPH Ahmedabad, and Dr. Kiran Kale, Ayurveda Physician and Assistant Director of CCRAS, Ahmedabad, are coordinating the event.

Similar integrative meetings were organised in New Delhi, Pune, Gorakhpur, and Varanasi during August and October 2025 to discuss arthritis and increase awareness and knowledge in the community and medical faculty. Following Ahmedabad, similar conferences are planned in Calicut, Bangalore, Chennai, Hyderabad, Kolkata, and Guwahati.

The post Top Rheumatologists Gather for Autoimmune disease meet appeared first on Health Vision.

New Delhi, 3rd November 2025: Motorica, a global MedTech company specializing in assistive technologies and medical cybernetics, has unveiled Omni Hand, world’s first bionic hand prosthesis equipped with optical myography (OMG) sensors. The launch marks a major leap forward in human–technology interaction and intuitive prosthetic control.

Moving beyond the limitations of traditional muscle-signal prosthetics, the Omni Hand leverages optical sensors to capture minute changes in tissue light transmittance caused by the movement of muscles and tendons. By interpreting these subtle variations in real time, the prosthesis translates even the smallest impulses into natural, precise motion. This breakthrough extends the benefits of advanced prosthetics to individuals with limited muscle activity, such as those recovering from electrical injuries, frostbite, or trauma, making intuitive and responsive control accessible to a wider spectrum of users.
“Omni Hand represents a new level of human-technology interaction. It doesn’t just respond to movement, it understands the user’s intent. This is a step toward truly natural control of bionic prosthetics,” said Andrei Davidiuk, CEO of Motorica.

The prosthesis is designed to recognize a set of the user’s “phantom gestures”, movements the brain imagines making with the missing hand, such as clenching a fist, making a pinch, or pointing. The Omni Hand can recognize and execute up to six individual gestures without the need to switch modes, ensuring fast, effortless, and adaptive control. Powered by an advanced user decision support system, the technology continuously learns from each interaction, adapting to the individual’s control patterns and improving precision over time, effectively enabling the prosthesis to evolve alongside the user.
While optical sensing in prosthetics has long remained within the realm of research, Cyber Motorica has become the first company to translate this breakthrough into real-world use. The successful pilot rollout, with the first eight users already integrating Omni Hand into their daily lives, marks a significant step forward in practical adoption and user experience. With mass production planned for 2026, the company is poised to make advanced, intuitive prosthetic control accessible to users on a global scale.

About the brand

Motorica is a top-10 global company in the upper limb prosthetics market. It develops and manufactures functional upper and lower limb prostheses for both adults and children from the age of 2. Since its founding in 2015, the company has produced over 9,000 prostheses for patients from 17 countries, including individuals from India, Vietnam, the MENA region, and Russia. In 2024, Motorica won the BRICS Solutions Award in the category of Biotechnology and National Health Care. The company specializes in rare types of injuries and offers the widest range of hand prostheses in the world. In 2025, Motorica opened its first office in New Delhi. In India, it already collaborates closely with over 25 clinics across key states, including Delhi NCR, Maharashtra, Karnataka, Uttar Pradesh, Tamil Nadu, as well as in several other regions nationwide.

Motorica implements 3D printing using SLS laser sintering, metalworking, robotics, microelectronics, and other advanced technologies in its prostheses. The company offers prostheses with natural skin-tone finishes to make the limb look almost indistinguishable from the lost one. It also has its own design studio to manufacture prostheses according to individual designs.

Since 2021, Motorica has been conducting innovative research aimed at restoring sensory perception in amputees and reducing phantom pain. This technology involves stimulation of the peripheral nervous system through implanted electrodes in patients’ limbs. Currently, participants using the prototype of the new prostheses can distinguish between hard and soft objects, as well as determine their size.

In 2024, Motorica expanded into the leg prostheses market by launching carbon foot models in partnership with a leading company IB-ER (Turkey). This partnership is a response to the growing demand for foot prostheses in India and other markets.

The post Motorica Introduces Innovative Bionic Hand Prosthesis appeared first on Health Vision.

The post Kannada Rajyotsava #vydyaloka #healthvision appeared first on Health Vision.

Ahmedabad: Shalby Hospital Naroda has achieved a major milestone with the successful completion of its first kidney transplant, showcasing the hospital’s specialised healthcare capabilities.

The recipient, Kalpesh Patel, 37, had been battling chronic kidney disease for several years. Since 2022, his kidney function had been gradually deteriorating, and by January 2025, it had fallen to less than 10%. Despite undergoing dialysis thrice a week, his health continued to decline, and his heart function had dropped to 25%, making his condition critical.

Dr. Mahendra Mulani, Consultant Nephrologist at Shalby Hospital Naroda, counselled Patel about the possibility of a kidney transplant, the only definitive treatment option for his condition, after which Patel’s father volunteered to donate a kidney.

Both donor and recipient underwent a series of extensive evaluations conducted by the expert multidisciplinary team comprising Dr. Mulani, Dr. Kosha Patel, Dr. Kirtipal Visana, and Dr. Darshit Shah to ensure medical fitness and compatibility for the transplant. The transplant surgery was performed at Shalby Hospital Naroda after receiving final approval from the government.

Patel’s recovery was swift and encouraging. His kidney function improved within days, creatinine levels returned to normal, and his overall health stabilised. His appetite and strength have returned, and he is expected to resume normal activities soon after completing his recovery period. The donor has also made a full recovery and remains in good health.

Patel’s recovery was swift and encouraging. His kidney function improved within days, creatinine levels returned to normal, and his overall health stabilised. His appetite and strength have returned, and he is expected to resume normal activities soon after completing his recovery period. The donor has also made a full recovery and remains in good health.

Commenting on the surgery, Dr. Mulani said, “This successful kidney transplant marks a new beginning for Kalpesh Patel and his family. It also highlights Shalby Hospital Naroda’s expertise in advanced renal care. Organ transplantation can restore health and happiness and offers hope to the many patients on dialysis who dream of a better quality of life.”

The post Shalby Hospital Naroda conducts its first kidney transplant appeared first on Health Vision.

Ahmedabad: Cadila Pharmaceuticals, one of India’s leading research-driven pharmaceutical companies, has launched Dlorfast-M-Tablets, a new fixed-dose combination therapy containing Desloratadine (5 mg) and Montelukast (10 mg). The product is designed for the management of allergic rhinitis and urticaria and marks an important advance in addressing the growing burden of allergic disorders in India.

Allergic rhinitis and urticaria are chronic conditions that affect millions of people worldwide, causing recurrent sneezing, nasal congestion, itching, hives, and swelling. These conditions can significantly reduce productivity, impair sleep quality, and diminish overall well-being. In India, allergy-related health problems have increased steadily over the past decade, driven by factors such as rising pollution levels, changing lifestyles, and genetic predisposition.

Recognising this challenge, Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response, namely histamine and leukotriene, to provide broader and more effective symptom relief.

Desloratadine is a potent and selective histamine H₁-receptor antagonist that blocks histamine, the primary mediator responsible for itching, swelling, and other allergy symptoms. Montelukast is a highly selective leukotriene receptor antagonist that binds with high affinity to cysteinyl leukotriene receptors, preventing airway oedema, smooth muscle contraction, and other inflammatory reactions. Together, the combination works synergistically to deliver comprehensive relief that is superior to either antihistamines or leukotriene inhibitors alone.

Clinical evaluations have shown that the Desloratadine and Montelukast combination significantly improves respiratory allergic pathology symptoms. The once-daily dosage enhances patient compliance and tolerability, making it suitable for long-term management of allergies. Dlorfast-M – Tablet is indicated for adults and adolescents with allergic rhinitis and urticaria. It is administered orally once daily as a single tablet.

Commenting on the launch, Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals Limited, said: “With the launch of Dlorfast-M, Cadila Pharmaceuticals continues its mission to provide accessible, effective, and innovative therapies to patients. This dual-action formulation addresses both histamine and leukotriene pathways, offering superior symptom control and improving quality of life for people living with allergies.”

Cadila Pharmaceuticals has a strong track record in respiratory and allergy care. The introduction of Dlorfast-M strengthens the company’s portfolio in this therapeutic area and underscores its commitment to delivering world-class, affordable healthcare solutions for patients across India and beyond.

Also read News of Cadila Pharmaceuticals

The post Cadila Launches Dlorfast-M Tablets for Fast Allergy Relief appeared first on Health Vision.